305 Results

People

  1. Seidman
    Seidman
  2. Aghajanian
    Aghajanian
  3. De Angelis
    De Angelis
  4. Hudis
    Hudis
  5. Kelsen
    Kelsen
  6. Lichtman
    Lichtman
  7. Saltz
    Saltz
  8. Scher
    Scher
  9. Bajorin
    Bajorin
  10. Fornier
    Fornier

Groups

  1. Department of Medicine (206)
  2. Solid Tumor Oncology Division (153)
  3. Survivorship Research (59)
  4. Hematologic Malignancies, Division of (51)
  5. Center for Hematologic Malignancies (47)
  6. Breast Medicine Service (43)
  7. Gastrointestinal Oncology Service (37)
  8. Surgery (29)
  9. Genitourinary Oncology Service (28)
  10. Center for Pancreatic Cancer Research (26)
  1. "peripheral neuropathy"
Formats
  1. Journal Article (283)
  2. Review (10)
  3. Conference Paper (6)
  4. Correspondence (3)
  5. Book Section (2)
  6. Guidelines (1)
Groups
  1. Department of Medicine (206)
  2. Solid Tumor Oncology Division (153)
  3. Survivorship Research (59)
  4. Hematologic Malignancies, Division of (51)
  5. Center for Hematologic Malignancies (47)
  6. Breast Medicine Service (43)

More Groups

People
  1. Andrew Seidman (16)
  2. Carol Aghajanian (12)
  3. Lisa De Angelis (12)
  4. Clifford Hudis (10)
  5. David Kelsen (10)
  6. Howard Scher (10)

More People

Years
  1. 2025 (9)
  2. 2024 (15)
  3. 2023 (19)
  4. 2022 (11)
  5. 2021 (7)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (26)
  2. Gynecologic Oncology (15)
  3. Lancet Oncology (14)
  4. Cancer (10)
  5. Annals of Oncology (9)
  6. Clinical Cancer Research (9)

More Publications

Publishers
  1. Elsevier Inc. (56)
  2. American Society of Clinical Oncology (26)
  3. Elsevier Science, Inc. (25)
  4. Springer (20)
  5. Wiley Blackwell (17)
  6. Oxford University Press (15)

More Publishers

Results (305)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study
    Journal Article

    Shitara, K.; Rha, S. Y.; Wyrwicz, L. S.; Oshima, T.; Karaseva, N.; Osipov, M.; Yasui, H.; Yabusaki, H.; Afanasyev, S.; Park, Y. K.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • In reply to Onjukka et al
    Correspondence

    Milano, M. T.; Mavroidis, P.; Yorke, E.; Ryckman, J.; Kong, F. M. S.; Grimm, J.; Marks, L. B.
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Rebuttal to comment on “concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer”
    Correspondence

    Han, J. E.; Zakeri, K.; Michel, L.; Sherman, E. J.; Lee, N. Y.
    Head & Neck (2024)

    Fulltext@MSK | Save
  • First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
    Journal Article

    Janku, F.; Kim, T. M.; Iyer, G.; Spreafico, A.; Elez, E.; de Jonge, M.; Yamamoto, N.; van der Wekken, A. J.; Ascierto, P. A.; Maur, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    Journal Article

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial
    Journal Article

    Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo Cid, R.; Chandana, S. R.; De La Fouchardière, C.; Dean, A.; Kiss, I.; Lee, W. J.; Goetze, T. O.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
    Journal Article

    Han, S. N.; Oza, A.; Colombo, N.; Oaknin, A.; Raspagliesi, F.; Wenham, R. M.; Braicu, E. I.; Jewell, A.; Makker, V.; Krell, J.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma
    Journal Article

    Klempner, S. J.; Lee, K. W.; Shitara, K.; Metges, J. P.; Lonardi, S.; Ilson, D. H.; Fazio, N.; Kim, T. Y.; Bai, L. Y.; Moran, D.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Neurodegenerative disease after hematopoietic stem cell transplantation in metachromatic leukodystrophy
    Journal Article

    Al-Saady, M.; Beerepoot, S.; Plug, B. C.; Breur, M.; Galabova, H.; Pouwels, P. J. W.; Boelens, J. J.; Lindemans, C.; van Hasselt, P. M.; Matzner, U.; more...
    Annals of Clinical and Translational Neurology (2023)

    Fulltext@MSK | Save